Welcome to our community as a Corporate Partner
EAS members form a global community of research scientists and healthcare professionals who share knowledge about the causes, natural history, treatment and prevention of atherosclerosis and related diseases. Working together we advance research, and improve management of these diseases in the clinic.
Corporate Partnership support allows us to carry out the activities in our educational and publishing programmes, to stimulate development in research into atherosclerosis and its causes, and to provide education in clinical practice management of dyslipidaemias, cardiovascular risk, and optimisation of patient care. These activities benefit the whole atherosclerosis scientific and medical community.
We invite industry partners to consider support to projects within the framework of the Society’s education, publishing and outreach programmes. Support to these activities counts towards recognition as a Corporate Partner of EAS.
Acknowledgement of current partners
We acknowledge the support, through grants and/or sponsorship, towards the education, publishing and outreach programmes of EAS. Listings based on support received during 2025.
Platinum-Level
Gold-Level
Silver-Level
Bronze-Level
Project supporters
EAS is pleased to acknowledge receipt of financial support to cover costs of ongoing activites in our publishing and educational programme from the following companies:
- Amgen
- Arrowhead
- AstraZeneca
- Caristo
- Denka
- Eli Lilly and Company
- Marea
- Mediquest India, with Torrent
- Menarini
- Novartis Mexico
- Novo Nordisk
- Raisio
- Sanofi
- Viatris
Opportunities for partnership
Contact Society Development & Corporate Relations Manager, Carmel Hayes, [email protected]